JP2014500278A - 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 - Google Patents

二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 Download PDF

Info

Publication number
JP2014500278A
JP2014500278A JP2013543410A JP2013543410A JP2014500278A JP 2014500278 A JP2014500278 A JP 2014500278A JP 2013543410 A JP2013543410 A JP 2013543410A JP 2013543410 A JP2013543410 A JP 2013543410A JP 2014500278 A JP2014500278 A JP 2014500278A
Authority
JP
Japan
Prior art keywords
dose
days
composition
interval
indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013543410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500278A5 (enExample
Inventor
シャーロッテ マクドナフ
フランシス ギボンズ
ビクター モイオ
Original Assignee
メリマック ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリマック ファーマシューティカルズ インコーポレーティッド filed Critical メリマック ファーマシューティカルズ インコーポレーティッド
Publication of JP2014500278A publication Critical patent/JP2014500278A/ja
Publication of JP2014500278A5 publication Critical patent/JP2014500278A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013543410A 2010-12-10 2011-12-12 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 Withdrawn JP2014500278A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42199210P 2010-12-10 2010-12-10
US61/421,992 2010-12-10
PCT/US2011/064496 WO2012079093A2 (en) 2010-12-10 2011-12-12 Dosage and administration of bispecific scfv conjugates

Publications (2)

Publication Number Publication Date
JP2014500278A true JP2014500278A (ja) 2014-01-09
JP2014500278A5 JP2014500278A5 (enExample) 2015-01-29

Family

ID=46207797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543410A Withdrawn JP2014500278A (ja) 2010-12-10 2011-12-12 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与

Country Status (6)

Country Link
US (1) US20140017264A1 (enExample)
EP (1) EP2648753A4 (enExample)
JP (1) JP2014500278A (enExample)
AU (1) AU2011341337A1 (enExample)
CA (1) CA2819554A1 (enExample)
WO (1) WO2012079093A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131113T1 (hr) 2007-02-16 2014-01-17 Merrimack Pharmaceuticals, Inc. Protutijela protiv erbb3 i njihova uporaba
JP2013522237A (ja) 2010-03-11 2013-06-13 メリマック ファーマシューティカルズ インコーポレーティッド トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
US20140056898A1 (en) * 2011-02-24 2014-02-27 Bo Zhang Combination therapies comprising anti-erbb3 agents
MX2014005411A (es) 2011-11-04 2015-02-12 Novartis Ag Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
EP2847226A4 (en) * 2012-05-11 2016-05-11 Merrimack Pharmaceuticals Inc DOSAGE AND ADMINISTRATION OF BIS SPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTICROBIAL AGENTS
US20150202287A1 (en) * 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2016022723A1 (en) 2014-08-05 2016-02-11 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
MX2010011145A (es) * 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.

Also Published As

Publication number Publication date
US20140017264A1 (en) 2014-01-16
WO2012079093A2 (en) 2012-06-14
WO2012079093A3 (en) 2013-08-08
CA2819554A1 (en) 2012-06-14
EP2648753A2 (en) 2013-10-16
EP2648753A4 (en) 2015-06-24
AU2011341337A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
JP2014500278A (ja) 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与
US12377144B2 (en) Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
DK2641601T3 (en) Methods for treating multiple myeloma using the combination therapy based on HuLuc63 with bortezomib
TWI513465B (zh) 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
KR20210142609A (ko) Ror1 항체 면역접합체로의 암 치료
KR20200112867A (ko) 길항적 항-pd-1 항체로 암을 치료하는 방법
CN104487088A (zh) 治疗gd2阳性癌的方法
CN104487089A (zh) 组合疗法
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
US20050112061A1 (en) Use of a VEGF antagonist in combination with radiation therapy
KR20150109386A (ko) 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체
TW202330040A (zh) 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2022502411A (ja) 非小細胞肺がんの処置のためのａｘｌ特異的抗体
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
CN118806923A (zh) 西妥昔单抗-ir700偶联物组合物
WO2023172906A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
CN117940169A (zh) 抗体药物偶联物的用途及联合用药物及其用途
US20250195466A1 (en) CXCR4/CXCR7 Blockade and Treatment of Human Papilloma Virus-Associated Disease
JP2023551432A (ja) グロボ系列抗原による免疫モジュレーションによる活動性がん免疫療法
CN117224689B (zh) 联合抗her2抗体和化疗剂治疗胃癌的用途
JP7780824B2 (ja) Ｈｅｒ２ワクチン組成物
WO2024183622A1 (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
KR20210097101A (ko) 표적화 모이어티-약물 이식된 면역 세포 조성물 및 사용 방법
CN111565719A (zh) 用于治疗食管癌的crac通道调节剂
JP2024534675A (ja) Ｈｓｐ９０抗原性ペプチドを含む抗癌用ワクチン組成物及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150325

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150717